ASCO GU 2018: Impact of Sexual Orientation on Contemporary Rates of Prostate Cancer Screening
San Francisco, CA (UroToday.com) Dr. Daniel Pucheril and colleagues presented their findings regarding the impact of sexual orientation on contemporary rates of prostate cancer screening. Although there has been increasing societal acceptance of non-heterosexual individuals, sexual minorities continue to face discrimination. The effect of non-heterosexual orientation on adoption of cancer preventive services, specifically prostate cancer screening, is essentially unknown.
ASCO GU 2018: Why are Low-risk Prostate Cancers (Pca) Treated Aggressively? A Population-based Cohort Analysis
San Francisco, CA (UroToday.com) Dr. Ramsankar Basak presented on the assessment he and his colleagues performed in which they utilized a population-level analysis to assess why men with low-risk prostate cancer are treated aggressively. As per the AUA guidelines , active surveillance is the best option for men with very low-risk prostate cancer and preferred option for all low-risk patients. However, despite improved adoption, active surveillance continues to be underused.
ASCO GU 2018: Statin use and Outcomes of Patients with mCRPC Being Treated with Abiraterone
San Francisco, CA (UroToday.com) Epidemiologic studies have demonstrated an association between statin use and improved prostate cancer specific mortality. Several different biologic mechanisms for such an effect have been proposed, including a potential role in reducing androgen precursor bioavailability. The authors have hypothesized that statins may therefore improve outcomes specifically in patients treated with the CYP17 inhibitor Abiraterone (ABI). Di Lorenzo (2017) recently published an analysis of 187 pts showing a relationship between ABI and improved survival (OS).
ASCO GU 2018: A National Survey of Radiation Oncologists and Urologists on Active Surveillance for Low-risk Prostate Cancer
San Francisco, CA (UroToday.com) Dr. Albert Kim and colleagues from Cleveland, OH presented results of their national survey of radiation oncologists and urologists on active surveillance for low-risk prostate cancer at today’s prostate cancer poster session at GU ASCO. Secondary to the growing concerns about over-diagnosis and overtreatment of localized prostate cancer, active surveillance has become an integral part of clinical practice guidelines.
ASCO GU 2018: When Can Active Surveillance Be Less Active? Prediction of Long-term Non-reclassification for Men with Low-risk Prostate Cancer
San Francisco, CA (UroToday.com) Matthew Cooperberg, MD presented results of predictors of long-term non-reclassification for men with low-risk prostate cancer. Active surveillance is endorsed as the preferred management strategy for most men with low-risk prostate cancer. However, nearly all active surveillance protocols entail PSA testing every 3-6 months, and prostate biopsies every 1-2 years, with no defined taper/end point for vigorous surveillance.
ASCO GU 2018: TPS 159 -What Fixes PSA Screening Guidelines Gone Wrong?
San Francisco, CA (UroToday.com) The authors report their study examining patient factors that alter correct recommendation and physician (MD) advice in real-time cancer screening discussions in a 2x2 cluster-randomized trial of MD educational supports.
ASCO GU 2018: Can free PSA be used as a biomarker in biochemical recurrence after surgery to predict CRPC?
San Francisco, CA (UroToday.com) Dr. Goldberg and colleagues from the Princess Margaret Cancer Centre in Toronto, Canada presented results of assessing free PSA in the setting of biochemical recurrence (BCR) after radical prostatectomy for predicting time to CRPC. PSA produced from prostate cancer cells escapes proteolytic processing, resulting in a more complexed PSA and a lower %free PSA (%fPSA). Higher %fPSA correlates with lower prostate cancer risk.